Curis gets Nasdaq delisting determination after 30 days below $1.00; plans to appeal

CURIS INC

• Nov 2, 2026 letter from Nasdaq Listing Qualifications Staff: bid price closed below $1.00 for 30 consecutive business days, violating Rule 5550(a)(2).
• No compliance period available: Curis' 1-for-20 reverse stock split on July 6, 2026 triggers the Rule 5810(c)(3)(A)(iv) bar on cure periods.
• Company is also under a one-year Discretionary Panel Monitor tied to the Nasdaq Hearings Panel decision dated July 24, 2026 (Rule 5815(d)(4)(A)).
• Curis intends to timely request a new hearing, which would stay further delisting action; it warns there is no assurance the appeal succeeds or listing continues.
• Signed by CFO Diantha Duvall; the filing's forward-looking statement cites risk factors in the 10-K for FY ended Dec 31, 2025.